Adaptive single-KIR+NKG2C+ NK cells expanded from select superdonors show potent missing-self reactivity and efficiently control HLA-mismatched acute myeloid leukemia

被引:24
作者
Haroun-Izquierdo, Alvaro [1 ]
Vincenti, Marianna [2 ]
Netskar, Herman [2 ]
van Ooijen, Hanna [3 ]
Zhang, Bin [4 ]
Bendzick, Laura [4 ]
Kanaya, Minoru [2 ]
Momayyezi, Pouria [1 ]
Li, Shuo [2 ]
Wiiger, Merete Thune [2 ]
Hoel, Hanna Julie [2 ]
Krokeide, Silje Zandstra [2 ]
Kremer, Veronika [1 ]
Tjonnfjord, Geir [5 ,6 ]
Berggren, Stephanie [7 ]
Wikstroem, Kristina [7 ]
Blomberg, Pontus [7 ]
Alici, Evren [8 ]
Felices, Martin [4 ]
oenfelt, Bjoern [3 ,9 ]
Hoeglund, Petter [8 ,10 ]
Valamehr, Bahram [11 ]
Ljunggren, Hans-Gustaf [1 ]
Bjoerklund, Andreas [1 ]
Hammer, Quirin [1 ]
Kveberg, Lise [2 ]
Cichocki, Frank [4 ]
Miller, Jeffrey S. [4 ]
Malmberg, Karl-Johan [1 ,2 ]
Sohlberg, Ebba [1 ]
机构
[1] Karolinska Inst, Ctr Infect Med, Dept Med Huddinge, Stockholm, Sweden
[2] Univ Oslo, Oslo Univ Hosp, Inst Canc Res, Dept Canc Immunol, Oslo, Norway
[3] KTH Royal Inst Technol, Dept Appl Phys, Sci Life Lab, Stockholm, Sweden
[4] Univ Minnesota, Masonic Canc Ctr, Minneapolis, MN USA
[5] Univ Oslo, Oslo Univ Hosp, Inst Clin Med, Dept Hematol, Oslo, Norway
[6] Univ Oslo, Inst Clin Med, KG Jebsen Ctr B cell malignancies, Oslo, Norway
[7] Karolinska Univ Hosp, Karolinska Ctr, Cell Therapy Clin Res Ctr, Vecura, Stockholm, Sweden
[8] Karolinska Inst, Ctr Hematol & Regenerat Med, Dept Med Huddinge, Stockholm, Sweden
[9] Karolinska Inst, Dept Microbiol Tumour & Cell Biol, Stockholm, Sweden
[10] Karolinska Univ Hosp, Dept Clin Immunol & Transfus Med, Stockholm, Sweden
[11] Fate Therapeut Inc, La Jolla, CA USA
关键词
killer cells; natural; immunotherapy; adoptive; immunity; innate; NATURAL-KILLER-CELLS; RELAPSE RISK EVIDENCE; IN-VIVO EXPANSION; CYTOMEGALOVIRUS-INFECTION; KIR; TRANSPLANTATION; ALLOREACTIVITY; REACTIVATION; REPERTOIRE;
D O I
10.1136/jitc-2022-005577
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
BackgroundNatural killer (NK) cells hold great promise as a source for allogeneic cell therapy against hematological malignancies, including acute myeloid leukemia (AML). Current treatments are hampered by variability in NK cell subset responses, a limitation which could be circumvented by specific expansion of highly potent single killer immunoglobulin-like receptor (KIR)(+)NKG2C(+) adaptive NK cells to maximize missing-self reactivity.MethodsWe developed a GMP-compliant protocol to expand adaptive NK cells from cryopreserved cells derived from select third-party superdonors, that is, donors harboring large adaptive NK cell subsets with desired KIR specificities at baseline. We studied the adaptive state of the cell product (ADAPT-NK) by flow cytometry and mass cytometry as well as cellular indexing of transcriptomes and epitopes by sequencing (CITE-Seq). We investigated the functional responses of ADAPT-NK cells against a wide range of tumor target cell lines and primary AML samples using flow cytometry and IncuCyte as well as in a mouse model of AML.ResultsADAPT-NK cells were >90% pure with a homogeneous expression of a single self-HLA specific KIR and expanded a median of 470-fold. The ADAPT-NK cells largely retained their adaptive transcriptional signature with activation of effector programs without signs of exhaustion. ADAPT-NK cells showed high degranulation capacity and efficient killing of HLA-C/KIR mismatched tumor cell lines as well as primary leukemic blasts from AML patients. Finally, the expanded adaptive NK cells had preserved robust antibody-dependent cellular cytotoxicity potential and combination of ADAPT-NK cells with an anti-CD16/IL-15/anti-CD33 tri-specific engager led to near-complete killing of resistant CD45(dim) blast subtypes.ConclusionsThese preclinical data demonstrate the feasibility of off-the-shelf therapy with a non-engineered, yet highly specific, NK cell population with full missing-self recognition capability.
引用
收藏
页数:13
相关论文
共 50 条
  • [1] TOX reinforces the phenotype and longevity of exhausted T cells in chronic viral infection
    Alfei, Francesca
    Kanev, Kristiyan
    Hofmann, Maike
    Wu, Ming
    Ghoneim, Hazem E.
    Roelli, Patrick
    Utzschneider, Daniel T.
    von Hoesslin, Madlaina
    Cullen, Jolie G.
    Fan, Yiping
    Eisenberg, Vasyl
    Wohlleber, Dirk
    Steiger, Katja
    Merkler, Doron
    Delorenzi, Mauro
    Knolle, Percy A.
    Cohen, Cyrille J.
    Thimme, Robert
    Youngblood, Benjamin
    Zehn, Dietmar
    [J]. NATURE, 2019, 571 (7764) : 265 - +
  • [2] The DifferentialNet database of differential protein-protein interactions in human tissues
    Basha, Omer
    Shpringer, Rotem
    Argov, Chanan M.
    Yeger-Lotem, Esti
    [J]. NUCLEIC ACIDS RESEARCH, 2018, 46 (D1) : D522 - D526
  • [3] Multidimensional Analyses of Donor Memory-Like NK Cells Reveal New Associations with Response after Adoptive Immunotherapy for Leukemia
    Berrien-Elliott, Melissa M.
    Cashen, Amanda F.
    Cubitt, Celia C.
    Neal, Carly C.
    Wong, Pamela
    Wagner, Julia A.
    Foster, Mark
    Schappe, Timothy
    Desai, Sweta
    McClain, Ethan
    Becker-Hapak, Michelle
    Foltz, Jennifer A.
    Cooper, Matthew L.
    Jaeger, Natalia
    Srivatsan, Sridhar Nonavinkere
    Gao, Feng
    Romee, Rizwan
    Abboud, Camille N.
    Uy, Geoffrey L.
    Westervelt, Peter
    Jacoby, Meagan A.
    Pusic, Iskra
    Stockerl-Goldstein, Keith E.
    Schroeder, Mark A.
    DiPersio, John
    Fehniger, Todd A.
    [J]. CANCER DISCOVERY, 2020, 10 (12) : 1854 - 1871
  • [4] NK cell responses to cytomegalovirus infection lead to stable imprints in the human KIR repertoire and involve activating KIRs
    Beziat, Vivien
    Liu, Lisa L.
    Malmberg, Jenny-Ann
    Ivarsson, Martin A.
    Sohlberg, Ebba
    Bjorklund, Andreas T.
    Retiere, Christelle
    Sverremark-Ekstrom, Eva
    Traherne, James
    Ljungman, Per
    Schaffer, Marie
    Price, David A.
    Trowsdale, John
    Michaelsson, Jakob
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    [J]. BLOOD, 2013, 121 (14) : 2678 - 2688
  • [5] FcεRIγ-negative NK cells persist in vivo and enhance efficacy of therapeutic monoclonal antibodies in multiple myeloma
    Bigley, Austin B.
    Spade, Shanae
    Agha, Nadia H.
    Biswas, Sujit
    Tang, Suni
    Malik, Muhammad H.
    Dai, Lu
    Masoumi, Shalaleh
    Patino-Escobar, Bonell
    Hale, Martina
    DiPierro, Guy
    Martell, Ronald
    Hann, Byron
    Shah, Nina
    Wiita, Arun P.
    Liu, Xinli
    [J]. BLOOD ADVANCES, 2021, 5 (15) : 3021 - 3031
  • [6] Complete Remission with Reduction of High-Risk Clones following Haploidentical NK-Cell Therapy against MDS and AML
    Bjorklund, Andreas T.
    Carlsten, Mattias
    Sohlberg, Ebba
    Liu, Lisa L.
    Clancy, Trevor
    Karimi, Mohsen
    Cooley, Sarah
    Miller, Jeffrey S.
    Klimkowska, Monika
    Schaffer, Marie
    Watz, Emma
    Wikstrom, Kristina
    Blomberg, Pontus
    Wahlin, Bjorn Engelbrekt
    Palma, Marzia
    Hansson, Lotta
    Ljungman, Per
    Hellstrom-Lindberg, Eva
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    [J]. CLINICAL CANCER RESEARCH, 2018, 24 (08) : 1834 - 1844
  • [7] Expression patterns of NKG2A, KIR, and CD57 define a process of CD56dim NK-cell differentiation uncoupled from NK-cell education
    Bjorkstrom, Niklas K.
    Riese, Peggy
    Heuts, Frank
    Andersson, Sandra
    Fauriat, Cyril
    Ivarsson, Martin A.
    Bjorklund, Andreas T.
    Flodstrom-Tullberg, Malin
    Michaelsson, Jakob
    Rottenberg, Martin E.
    Guzman, Carlos A.
    Ljunggren, Hans-Gustaf
    Malmberg, Karl-Johan
    [J]. BLOOD, 2010, 116 (19) : 3853 - 3864
  • [8] Defining 'T cell exhaustion'
    Blank, Christian U.
    Haining, W. Nicholas
    Held, Werner
    Hogan, Patrick G.
    Kallies, Axel
    Lugli, Enrico
    Lynn, Rachel C.
    Philip, Mary
    Rao, Anjana
    Restifo, Nicholas P.
    Schietinger, Andrea
    Schumacher, Ton N.
    Schwartzberg, Pamela L.
    Sharpe, Arlene H.
    Speiser, Daniel E.
    Wherry, E. John
    Youngblood, Benjamin A.
    Zehn, Dietmar
    [J]. NATURE REVIEWS IMMUNOLOGY, 2019, 19 (11) : 665 - 674
  • [9] CD56dimCD57+NKG2C+ NK cell expansion is associated with reduced leukemia relapse after reduced intensity HCT
    Cichocki, F.
    Cooley, S.
    Davis, Z.
    DeFor, T. E.
    Schlums, H.
    Zhang, B.
    Brunstein, C. G.
    Blazar, B. R.
    Wagner, J.
    Diamond, D. J.
    Verneris, M. R.
    Bryceson, Y. T.
    Weisdorf, D. J.
    Miller, J. S.
    [J]. LEUKEMIA, 2016, 30 (02) : 456 - 463
  • [10] Phase 1 clinical trial using mbIL21 ex vivo-expanded donor-derived NK cells after haploidentical transplantation
    Ciurea, Stefan O.
    Schafer, Jolie R.
    Bassett, Roland
    Denman, Cecele J.
    Cao, Kai
    Willis, Dana
    Rondon, Gabriela
    Chen, Julianne
    Soebbing, Doris
    Kaur, Indreshpal
    Gulbis, Alison
    Ahmed, Sairah
    Rezvani, Katayoun
    Shpall, Elizabeth J.
    Lee, Dean A.
    Champlin, Richard E.
    [J]. BLOOD, 2017, 130 (16) : 1857 - 1868